Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

About 25% of breast cancers harbor the amplified oncogene HER2 and are dependent on HER2 kinase function, identifying HER2 as a vulnerable target for therapy. However,. HER2-HER3 activation is buffered so that it is protected against a nearly two log inhibition of HER2 catalytic activity; this buffe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Amin, Dhara N., Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Blair, Jimmy A., Wang, Donghui, Hann, Byron, Koch, Kevin M., Shokat, Kevan M., Moasser, Mark M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033659/
https://ncbi.nlm.nih.gov/pubmed/20371474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3000389
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge